Moderna, Inc.: Moderna Reports First Quarter 2022 Financial

First quarter 2022 revenues of $6.1 billion; GAAP net-income of $3.7 billion and GAAP diluted EPS of $8.58Moderna reiterates its 2022 signed advance purchase agreements of approximately $21 billionCompany

Related Keywords

Kenya , Puerto Rico , Norway , Georgia , United States , Malaysia , Australia , Bangladesh , India , United Kingdom , Singapore , Cambridge , Cambridgeshire , Quebec , Canada , Australian , American , Republic Of Kenya , Jorge Gomez , Lavina Talukdar , Intratumoral Immuno , Arpa Garay , Dentsply Sirona , David Meline , Moderna Nipah , Moderna Atlanta , Colleen Hussey , Us Department Of Defense , Merck Human Health , Research Development , Moderna Executive Committee , Nasdaq , Development Expenses , Merck Co Inc , Astrazeneca , Information Technology , Moderna Inc , Vertex Pharmaceuticals , Company Recognition , Summary Of Program , Institute For Life Changing Medicines , National Institutes Of Health , World Health Organization , Drug Administration , Exchange Commission , American Association For Cancer Research , Global Public Health Strategy , Share Repurchase Program , Merck Co , Melinda Gates Foundation , Dentsply Sirona Inc , Vaccine Research Center , Moderna Charitable Foundation , Merck Executive Committee , Public Health Vaccines , Global Pharmaceuticals , Vaccine Initiative , Enterprise Solutions Hub In Atlanta , Corporate Communications , Moderna Enterprise Solutions Hub In Atlanta , Chief Executive Officer , Southern Hemisphere , Open Label Extension , Administrative Expenses , Income Taxes , Per Share , Cash Provided , Operating Activities , Common Stock , Purchase Agreements , Repurchase Program , Chief Financial Officer , Executive Committee , Executive Vice President , Corporate Audit , Investor Relations , Chief Commercial Officer , Chief Marketing Officer , Human Health , Digital Marketing , General Manager , Enterprise Solutions Hub , Australian Federal Government , Public Health Strategy , Analyst Event , Program Highlights , Biologics License Application , Northern Hemisphere , Receptor Binding Domain , N Terminal Domain , Fast Track , Melinda Gates , National Institutes , Research Center , Cell Surface Therapeutics , American Association , Cancer Research , Regenerative Therapeutics , Intracellular Therapeutics , Drug Designation , Crigler Najjar Syndrome Type , Rare Pediatric Disease , Life Changing Medicines , Months Ended March , Private Securities Litigation Reform Act , Annual Report , Vice President , Infect Dis Now , Moderna , Reports , First , Quarter , 022 , Financial , Results , Rovides , Business , Updates ,